DealsJun 1, 2026, 06:26 AM
MoonLake Enters Commercial Supply & Capacity Agreements with Vetter
AI Summary
MoonLake Immunotherapeutics entered into a Master Commercial Supply Agreement and a Capacity Agreement with Vetter Pharma International GmbH on May 22, 2026. The Master Commercial Supply Agreement outlines Vetter's manufacturing of pre-filled application systems for MoonLake's products, with product-specific schedules and adjustable pricing. The Capacity Agreement requires MoonLake to commit to annual demand forecasts, ensuring Vetter reserves filling capacity, with potential compensation obligations if minimum quantities are not met. These agreements build upon a previous development agreement for sonelokimab.
Key Highlights
- MoonLake signed a Master Commercial Supply Agreement with Vetter Pharma International GmbH.
- Vetter will manufacture pre-filled application systems for MoonLake's pharmaceutical products.
- The agreement allows for product-specific schedules detailing manufacturing services and pricing.
- Pricing may be adjusted by Vetter based on increases in its cost structure.
- MoonLake also entered a Capacity Agreement, committing to binding annual demand forecasts.
- Vetter will reserve filling capacity equivalent to MoonLake's maximum quantity per year.
- MoonLake may incur capacity compensation if minimum quantity commitments are not met.
- Agreements can be terminated for cause (60-day cure period) or without cause (12 months' notice).
Price Impact
More from MLTX